Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903373 | 0.88 | CYP1A1 (0.39) | NPC1RAB9ADHFRKMOHRH4 | |
| SCHEMBL11903363 | 0.88 | CYP1A1 (0.39) | NPC1RAB9ADHFRKMOHRH4 | |
| SCHEMBL17476606 | 0.84 | NPC1 (0.35) | NPC1RAB9ADHFRKMOADORA1 | |
| SCHEMBL11902833 | 0.80 | CYP1A1 (0.41) | ADORA1CYP1A1CYP1A2CYP1B1FGFR1 | |
| SCHEMBL14529191 | 0.78 | CYP1A1 (0.60) | NPC1RAB9ADHFRHRH4ADORA1 | |
| SCHEMBL867887 | 0.77 | CYP1A2 (0.39) | ADORA1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL11902447 | 0.77 | DHFR (0.47) | DHFR | |
| SCHEMBL11902828 | 0.77 | SYK (0.46) | — | |
| SCHEMBL28890947 | 0.76 | NPC1 (0.50) | NPC1RAB9ADHFRKMOHRH4 | |
| SCHEMBL867664 | 0.75 | MPL (0.44) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-9101632-B2 | Kinase inhibitors, prodrug forms thereof and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-08-11 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, ERBB3 | NPC1 3955/4885RAB9A 2155/4885DHFR 749/4885 |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, MAP3K19 | NPC1 4041/4885RAB9A 1926/4885DHFR 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.